Avonex
BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis
May 28, 2020Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis
Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …
FDA approves Biogen’s long-acting MS drug
August 18, 2014Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera
Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …
New MS drug shows promise for Abbott
August 10, 2011Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya
Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Abbott starts head-to-head MS trial
May 25, 2010Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab
Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …
Latest content
Pharma sees climate disruption as growing supply-chain risk
September 11, 2026
Manchester NHS-MHRA partnership to test new technologies in real-world care
September 10, 2026
